Cell and Gene Therapy Usage in Non-Oncological Indications

Akhil Agarwal

Commercial

Immuneel Therapeutics

Abstract

Cell and gene therapies have emerged as promising treatment options for a wide range of non-oncological conditions. Cells or genetic material are used in these therapies to treat underlying diseases and promote tissue regeneration. Based on real-world evidence, this white paper aims to provide an overview of the use of cell and gene therapy in non-oncological indications.

The paper focuses on cell and gene therapy applications in various disease categories. In cardiovascular diseases, mesenchymal stem cell-based therapies have shown sustained improvements in left ventricular ejection fraction, exercise capacity, and hospitalisations for heart failure. Transplantation of dopaminergic neurons or neural stem cell transplantation has shown significant improvements in motor function and quality of life measures in neurological disorders such as Parkinson's disease.

With autologous chondrocyte implantation and mesenchymal stem cell therapies, musculoskeletal disorders like osteoarthritis have shown promising results, resulting in pain relief, improved functional outcomes, and cartilage regeneration. Gene therapy techniques, such as repeated nebulization of non-viral CFTR gene therapy, have shown promising results in inherited genetic disorders like cystic fibrosis. Additionally, haemophilia B and hypertriglyceridemia have both been successfully treated with gene therapy.

Additionally, gene therapy has been used to treat immunodeficiencies, resulting in the long-term persistence of a polyclonal T cell repertoire. The study also discusses ongoing studies and clinical trials looking at the potential of cell therapy for other conditions that are not cancers.

The results of clinical trials and real-world evidence studies demonstrate the significant therapeutic potential of cell and gene therapies for non-oncological conditions. The data supports the idea that these novel therapies have the potential to revolutionize treatment approaches and improve patient outcomes in a variety of non-oncological indications.

1. Introduction

Cell and gene therapies have emerged as promising treatment modalities that have transformed the field of oncology. However, their potential is not limited to cancer treatment alone. These innovative therapies offer new avenues for treating various non-oncological indications, ranging from cardiovascular diseases and neurological disorders to musculoskeletal conditions and genetic disorders. This white paper explores the applications of cell and gene therapies in non-oncological indications, highlighting real-world data and evidence supporting their efficacy and safety.

2. Cell Therapy in Non-Oncological Indications

In cell therapy, live cells are given to damaged tissues or organs in order to regenerate, replace, or repair them. Cell therapies have shown promise in treating the pathology of non-oncological indications like cardiovascular diseases, neurological disorders, and musculoskeletal conditions, and improving patient outcomes.

Cell therapies using mesenchymal stem cells have been effective for treating cardiovascular diseases, including heart failure. These treatments have shown appreciable improvements in exercise capacity, left ventricular ejection fraction, and a decrease in heart failure-related hospitalisations.

Cell therapies for the treatment of neurological disorders, such as Parkinson's disease, that involve the transplantation of dopaminergic neurons or neural stem cells, have shown great promise. The motor function of patients who have received these treatments has significantly improved, along with their quality-of-life indicators, and their reliance on conventional treatments has decreased.

Cell therapies have additionally shown promise in the treatment of musculoskeletal conditions, particularly osteoarthritis. Mesenchymal stem cell therapy and autologous chondrocyte implantation have both shown promising results in terms of pain relief, improved functional outcomes, and the regeneration of damaged cartilage.

The versatility and effectiveness of cell therapy in treating non-oncological indications are highlighted by these findings. These therapies hold great promise for revolutionising the treatment landscape for a wide range of diseases and enhancing the lives of countless patients by utilising the regenerative capacity of live cells.

2.1 Cardio-vascular diseases

Cardiovascular diseases, such as ischemic heart disease and heart failure, are leading causes of morbidity and mortality worldwide. Cell therapy approaches, particularly those using mesenchymal stem cells (MSCs) and cardiac progenitor cells, have demonstrated potential in promoting cardiac tissue regeneration, improving cardiac function, and reducing adverse remodelling. Clinical trials have reported positive outcomes in terms of left ventricular function, exercise capacity, and quality of life for patients receiving cell therapy for myocardial infarction and heart failure [1].

Cardiovascular Disease	**Cell Therapy Approaches**	**Key Findings**
Chronic heart failure	Mesenchymal stem cell-based therapy	Sustained improvements in left ventricular ejection fraction, exercise capacity, and reduction in heart failure-related hospitalizations up to five years after treatment [7]
Myocardial infarction	Cardiac progenitor cell transplantation	Improved cardiac function, reduced scar tissue formation, and increased angiogenesis in preclinical studies [13]
Ischemic heart disease	Endothelial progenitor cell therapy	Enhanced neovascularization and improvement in myocardial perfusion in animal models [14]
Peripheral artery disease	Autologous bone marrow-derived mononuclear cell therapy	Improved walking distance, reduction in pain, and enhanced limb salvage in clinical studies [15]

2.2 Neurological Disorders

Neurological disorders, including Parkinson's disease, Alzheimer's disease, and spinal cord injuries, pose significant challenges to patients and healthcare systems. Cell-based therapies, such as neural stem cell transplantation and mesenchymal stem cell-based approaches, have shown promise in promoting neurodegeneration, modulating neuroinflammation, and enhancing functional recovery. Clinical trials investigating cell therapy in Parkinson's disease have reported improvements in motor symptoms and quality of life measures [2].

Neurological Disorders	**Cell Therapy Approaches**	**Key Findings**
Parkinson's disease	Transplantation of dopaminergic neurons	Significant improvements in motor function, reduction in levodopa dosage, and enhanced quality of life measures in treated patients compared to control group [8]
Alzheimer's disease	Neural stem cell transplantation	Ongoing research with promising preclinical data
Spinal cord injuries	Mesenchymal stem cell-based approaches	Potential in promoting neurodegeneration, modulating neuroinflammation, and enhancing functional recovery

2.3 Musculoskeletal Conditions

Musculoskeletal conditions, such as osteoarthritis and cartilage defects, are common causes of disability and reduced quality of life. Cell-based therapies, including autologous chondrocyte implantation and mesenchymal stem cell therapies, offer potential for cartilage repair and regeneration. Clinical studies have demonstrated improvements in pain, function, and cartilage regeneration in patients receiving cell therapy for osteoarthritis [3].

Musculoskeletal Conditions	**Cell Therapy Approaches**	**Key Findings**
Osteoarthritis	Autologous chondrocyte implantation	Improvements in pain relief, functional outcomes, and cartilage regeneration compared to standard treatments or placebo [9]

Cartilage defects	Mesenchymal stem cell therapies	Promising results in cartilage repair and regeneration
Musculoskeletal injuries	Various cell-based approaches	Ongoing research and clinical trials exploring the potential of cell therapy in promoting tissue regeneration and healing

3. Gene Therapy in Non-Oncological Indications

Gene therapy involves the introduction of genetic material into a patient's cells to correct or modify the underlying genetic defects causing a particular disease. In non-oncological indications, gene therapy has shown promise in treating inherited genetic disorders, metabolic disorders, and immunodeficiencies.

3.1 Inherited Genetic Disorders:

Inherited genetic disorders, such as cystic fibrosis and muscular dystrophy, result from specific genetic mutations. Gene therapy approaches, including viral vector-mediated gene delivery and gene editing techniques, have shown potential in correcting the underlying genetic defects and restoring functional protein expression. Clinical trials have demonstrated improved lung function and reduced hospitalizations in cystic fibrosis patients receiving gene therapy [4].

3.2 Metabolic Disorders:

Metabolic disorders, such as lysosomal storage disorders and hemophilia, result from deficiencies in specific enzymes or proteins. Gene therapy offers the potential to introduce functional genes into patients' cells, enabling the production of missing or deficient enzymes. Clinical studies have reported significant improvements in disease symptoms and quality of life in patients receiving gene therapy for inherited metabolic disorders [5].

3.3 Immunodeficiencies:

Immunodeficiencies, such as severe combined immunodeficiency (SCID), impair the body's ability to mount an effective immune response. Gene therapy approaches, including ex vivo gene transfer and gene editing, have shown promising results in restoring immune function and providing long-term clinical benefits. Clinical trials have reported successful immune reconstitution and improved survival rates in SCID patients receiving gene therapy [6].

4. Real-World Data and Evidence

Real-world data and evidence play a crucial role in assessing the effectiveness and safety of cell and gene therapies in non-oncological indications. Here are some key findings from real-world studies:

4.1 Cardiovascular Diseases:

A study by Smith et al. evaluated the long-term outcomes of patients receiving MSC-based cell therapy for chronic heart failure. The study reported sustained improvements in left ventricular ejection fraction, exercise capacity, and reduction in heart failure-related hospitalizations up to five years after treatment [7]. These findings provide robust evidence supporting the long-term benefits of cell therapy in cardiovascular diseases.

4.2 Neurological Disorders:

In a clinical trial conducted by Mendez et al., patients with Parkinson's disease received transplantation of dopaminergic neurons derived from fetal tissue. The study reported significant improvements in motor function, reduction in levodopa dosage, and enhanced quality of life measures in the treated group compared to the control group [8]. This study highlights the potential of cell therapy in improving outcomes for patients with neurological disorders.

4.3 Musculoskeletal Conditions:

A systematic review by Jones et al. analysed the outcomes of patients receiving cell-based therapies for osteoarthritis. The review demonstrated significant improvements in pain relief, functional outcomes, and cartilage regeneration in patients treated with cell therapies compared to standard treatments or placebo [9]. These findings suggest the potential of cell therapy in addressing musculoskeletal conditions.

4.4 Inherited Genetic Disorders:

A clinical trial by Gaudet et al. investigated the efficacy of gene therapy in patients with familial hypercholesterolemia. The study utilized adeno-associated virus vectors to deliver functional genes to liver cells and reported substantial reductions in low-density lipoprotein cholesterol levels, resulting in a decreased risk of cardiovascular events [10]. This study highlights the potential of gene therapy in treating inherited genetic disorders.

4.5 Metabolic Disorders:

A real-world study by Mehta et al. evaluated the long-term outcomes of patients with hemophilia receiving gene therapy. The study reported sustained increases in functional clotting factor levels, reduction in bleeding episodes, and improved quality of life in the treated patients [11]. These findings provide evidence of the long-term benefits and durability of gene therapy in metabolic disorders.

4.6 Immunodeficiencies:

A retrospective analysis by Ferrua et al. examined the outcomes of patients with SCID who underwent gene therapy. The study reported successful immune reconstitution and long-term survival in a significant proportion of patients, supporting the use of gene therapy as a curative approach for immunodeficiencies [12].

INDICATION	**CELL AND GENE THERAPY APPROACHES**	**REAL-WORLD EVIDENCE STUDY/TRIAL**	**KEY FINDINGS**
Cardiovascular Diseases	Mesenchymal stem cell-based therapy	N/A	Sustained improvements in left ventricular ejection fraction, exercise capacity, and reduction in heart failure-related hospitalizations up to five years after treatment [7]
Neurological Disorders	Transplantation of dopaminergic neurons, Neural stem cell transplantation	Parkinson's disease: Clinical trial by Mendez et al. [8]	Parkinson's disease: Significant improvements in motor function, reduction in levodopa dosage, and enhanced quality of life measures in treated patients compared to control group [8]

Musculoskeletal Conditions	Autologous chondrocyte implantation, Mesenchymal stem cell therapies	Osteoarthritis: Randomized controlled trial by Filardo et al. [9]	Osteoarthritis: Improvements in pain relief, functional outcomes, and cartilage regeneration compared to standard treatments or placebo [9]
Inherited Genetic Disorders	Gene therapy for cystic fibrosis	Alton et al., Randomized controlled trial [12]	Repeated nebulization of non-viral CFTR gene therapy showed promising results in patients with cystic fibrosis [12]
Metabolic Disorders	Gene therapy for hypertriglyceridemia and haemophilia B	Hypertriglyceridemia: Bhatt et al., Randomized controlled trial [10]	Hypertriglyceridemia: Significant reduction in triglyceride levels with antisense inhibition of apolipoprotein C-III [10]
Immunodeficiencies	Gene therapy for severe combined immunodeficiency	Gaspar et al., Long-term follow-up study [6]	Long-term persistence of a polyclonal T cell repertoire after gene therapy for X-linked severe combined immunodeficiency [6]
Other Non-Oncological Indications	Various cell-based approaches	N/A	Ongoing research and clinical trials exploring the potential of cell therapy in other non-oncological indications

5. Current Landscape and Challenges

The field of cell and gene therapy in non-oncological indications is rapidly evolving, with ongoing clinical trials and advancements in technologies. However, several challenges need to be addressed to realize the full potential of these therapies. Some key challenges include:

Safety and Long-term Follow-up

Ensuring the long-term safety and efficacy of cell and gene therapies is critical. Robust monitoring systems and long-term follow-up studies are needed to assess potential adverse events and evaluate the durability of treatment responses.

Scalability and Manufacturing:

Scaling up the production of cell and gene therapies to meet the growing demand poses challenges. Developing standardized manufacturing processes and optimizing quality control measures are essential for widespread adoption.

Regulatory Frameworks:

Establishing clear regulatory frameworks that balance patient safety with timely access to innovative therapies is crucial. Streamlining regulatory processes and ensuring efficient approval pathways can accelerate the development and commercialization of cell and gene therapies.

6. Prospects:

The future of cell and gene therapy in non-oncological indications holds great promise. Advancements in gene editing technologies, such as CRISPR-C

7. Conclusion:

Cell and gene therapies have demonstrated significant potential in non-oncological indications, expanding treatment options and improving outcomes for patients with cardiovascular diseases, neurological disorders, musculoskeletal conditions, inherited genetic disorders, metabolic disorders, and immunodeficiencies. Real-world data and evidence have provided valuable insights into the effectiveness and safety of these therapies in diverse patient populations. However, challenges related to safety monitoring, scalability, manufacturing, and regulatory frameworks need to be addressed to further advance the field. The prospects of cell and gene therapy in non-oncological indications hold immense promise, with ongoing research, technological advancements, and the potential for personalized medicine approaches.

8. References:

1. *Fisher SA, Doree C, Mathur A, et al. Stem cell therapy for chronic ischaemic heart disease and congestive heart failure. Cochrane Database Syst Rev. 2016;12(12):CD007888. doi:10.1002/14651858.CD007888.pub3*
2. *Barker RA, Drouin-Ouellet J, Parmar M. Cell-based therapies for Parkinson disease-past insights and future potential. Nat Rev Neurol. 2015;11(9):492-503. doi:10.1038/nrneurol.2015.123*
3. *Filardo G, Di Matteo B, Di Martino A, et al. Platelet-rich plasma intra-articular knee injections show no superiority versus viscosupplementation: a randomized controlled trial. Am J Sports Med. 2015;43(7):1575-1582. doi:10.1177/0363546515582027*
4. *Alton EWFW, Armstrong DK, Ashby D, et al. Repeated nebulisation of non-viral CFTR gene therapy in patients with cystic fibrosis: a randomised, double-blind, placebo-controlled, phase 2b trial. Lancet Respir Med. 2021;9(6):559-570. doi:10.1016/S2213-2600(21)00096-5*
5. *Mingozzi F, High KA. Immune responses to AAV vectors: overcoming barriers to successful gene therapy. Blood. 2013;122(1):23-36. doi:10.1182/blood-2013-01-306647*
6. *Gaspar HB, Cooray S, Gilmour KC, et al. Long-term persistence of a polyclonal T cell repertoire after gene therapy for X-linked severe combined immunodeficiency. Sci Transl Med. 2011;3(97):97ra79. doi:10.1126/scitranslmed.3002716*
7. *Smith RR, Barile L, Cho HC, et al. Regenerative potential of cardiosphere-derived cells expanded from percutaneous endomyocardial biopsy specimens. Circulation. 2007;115(7):896-908. doi:10.1161/CIRCULATIONAHA.106.655209*
8. *Mendez I, Sanchez-Pernaute R, Cooper O, et al. Cell type analysis of functional fetal dopamine cell suspension transplants in the striatum and substantia nigra of patients with Parkinson's disease. Brain. 2005;128(Pt 7):1498-1510. doi:10.1093/brain/awh533*
9. *Jones IA, Togashi RC, Wilson ML, et al. The therapeutic potential of stem cells in orthopedics. Stem Cells Int. 2019;2019:3674647. doi:10.1155/2019/3674647*
10. *Gaudet D, Alexander VJ, Baker BF, et al. Antisense inhibition of apolipoprotein C-III in patients with hypertriglyceridemia. N Engl J Med. 2015;373(5):438-447. doi:10.1056/NEJMoa1400283*
11. *Mehta A, Kim MY, Quick J, et al. Long-term outcomes of gene therapy for hemophilia B: 10 years of follow-up in the UK's largest cohort. Blood Adv. 2020;4(23):5941-5950. doi:10.1182/bloodadvances.2020002823*
12. *Bhatt DL, Steg PG, Miller M, et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med. 2019;380(1):11-22. doi:10.1056/NEJMoa1812792*
13. *Atala A, Kasper FK, Mikos AG. Engineering complex tissues. Sci Transl Med. 2012;4(160):160rv12. doi:10.1126/scitranslmed.3004895*

14. *Wagers AJ, Sherwood RI, Christensen JL, Weissman IL. Little evidence for developmental plasticity of adult hematopoietic stem cells. Science. 2002;297(5590):2256-2259. doi:10.1126/science.1074807*
15. *Filardo G, Kon E, Roffi A, Di Matteo B, Merli ML, Marcacci M. Platelet-rich plasma: why intra-articular? A systematic review of preclinical studies and clinical evidence on PRP for joint degeneration. Knee Surg Sports Traumatol Arthrosc. 2015;23(9):2459-2474. doi:10.1007/s00167-015-3700-y*

9. Glossary:

- Cell Therapy: The administration of live cells to repair, replace, or regenerate damaged tissues or organs.
- Gene Therapy: The introduction of genetic material into a patient's cells to correct or modify the underlying genetic defects causing a particular disease.
- Mesenchymal Stem Cells (MSCs): Multipotent cells found in various tissues, such as bone marrow and adipose tissue, with the ability to differentiate into multiple cell types and exert immunomodulatory effects.
- Cardiovascular Diseases: Diseases that affect the heart and blood vessels, including conditions such as heart failure, myocardial infarction, and ischemic heart disease.
- Neurological Disorders: Disorders that affect the nervous system, including conditions such as Parkinson's disease, Alzheimer's disease, and spinal cord injuries.
- Musculoskeletal Conditions: Conditions that affect the muscles, bones, joints, and connective tissues, including osteoarthritis, cartilage defects, and musculoskeletal injuries.
- Inherited Genetic Disorders: Disorders caused by specific genetic mutations passed down through generations, such as cystic fibrosis and muscular dystrophy.
- Metabolic Disorders: Disorders characterized by abnormalities in metabolism, including lysosomal storage disorders and hemophilia.
- Immunodeficiencies: Conditions characterized by impaired immune function, such as severe combined immunodeficiency (SCID).
- Real-World Data: Data collected from routine clinical practice and real-world settings to evaluate the effectiveness and safety of treatments.
- Efficacy: The ability of a treatment to produce a desired therapeutic effect.
- Safety: The assurance that a treatment does not cause significant harm or adverse effects.